Oramed Closes $5 Million Investment From Guangxi Wuzhou Pharmaceutical Company

JERUSALEM, Israel, December 3, 2014 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, today announced that it has received $5 million in connection with the definitive agreement with Guangxi Wuzhou Pharmaceutical Co., Ltd., a subsidiary of Guangxi Wuzhou Zhongheng Group […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals at LD MICRO “Main Event” Micro-Cap Growth Conference on December 2, 2014

JERUSALEM, December 1, 2014 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Company management will participate in the upcoming LD MICRO “Main Event” Micro-Cap Growth Conference taking place from December […]

Categories: 新闻通稿|Tags: |

Coverage Initiation Report Focuses on Oramed Pharmaceuticals

NEW YORK, NY — (Marketwired) — 11/11/14 —
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is the subject of a new in-depth initiation coverage repot by Acceleron Equity Research.
Interested investor may get more information and a copy of the coverage report at: http://acceleronequity.net/ORMP.html

[…]

Categories: 新闻通稿|Tags: |

Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes

Conference Call Scheduled for Monday, November 3, 2014 at 10:00 a.m. Eastern time

JERUSALEM, October 31, 2014 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)(http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announces that the company will host a conference call to […]

Categories: 新闻通稿|Tags: |

Oramed to Present at the FireRock Annual Micro-Cap Conference

Company CEO to present on October 28, 2014

JERUSALEM, October 24, 2014 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company’s CEO, Nadav Kidron will present at FireRock Capital’s Micro-Cap […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes

Demonstrates Proof-of-Concept for ORMD-0801 Oral Insulin to Reduce Exogenous Insulin Requirements

JERUSALEM, October 22, 2014 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://chinese.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today reported positive top-line clinical results from its Phase IIa […]

Categories: 新闻通稿|Tags: |

Oramed to Present at Family Office & Wealth Management Conference

Company CEO to present on September 17, 2014

JERUSALEM, September 15, 2014 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company’s CEO, Nadav Kidron will present at DC Finance’s Family Office […]

Categories: 新闻通稿|Tags: |

Oramed to Present at Upcoming Conferences

Company CEO to present at both the Rodman & Renshaw Global Investment Conference and Aegis Capital 2014 Healthcare and Technology Conference in September

JERUSALEM, September 3, 2014 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery […]

Categories: 新闻通稿|Tags: |

Oramed Granted Patent in Spain for Oral Administration of Insulin

JERUSALEM, August 19, 2014 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Spain has granted the Company’s patent for its invention, titled “Methods and Compositions […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes

Top-Line Data Expected in Q4 of 2014

JERUSALEM, August 7, 2014 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today reports that the last patient has completed treatment in its Phase IIa clinical trial […]

Categories: 新闻通稿|Tags: |